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Abstract
The objective of this study was to assess health related quality of life (QOL) in patients with type I diabetes
mellitus (DMT1) and to compare their QOL with the QOL of persons of comparable age in the general
population. Furthermore we wanted to investigate which factors mostly inﬂuence QOL. In a Dutch cohort
of 281 patients with DMT1 QOL was assessed using two generic instruments: the EuroQol and the RAND-
36. We performed regression analyses to investigate relationships between several demographic (e.g. sex,
age, marital status) and diabetes-speciﬁc variables (e.g. HbA1c, frequency of insulin injection, presence of
acute and chronic complications) and QOL. The Spearman rank correlations between RAND-36 domains
and EuroQol were analysed. RAND-36 results showed, for almost all domains, a QOL comparable with
persons of comparable age in the general population. In contrast the QOL measured with the EuroQol was
lower for subjects with DMT1. Hyperglycaemic complaints and macrovascular complications had a pro-
found negative inﬂuence on QOL. Most correlations between the RAND-36 results and the EuroQol
results corresponded with our expectations. Longitudinal data and comparison with results of several
diabetes-speciﬁc questionnaires should help to establish which instrument might be most appropriate to
measure QOL in patients with DMT1.
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Introduction
Diabetes mellitus type I (DMT1) is a chronic dis-
ease caused by auto-immune destruction of the
insulin-producing pancreatic beta cells resulting in
an absolute inability to produce insulin, necessary
for the regulation of blood glucose [1].
The primary goal of treatment is to reach ade-
quate metabolic control by daily insulin injections
to avoid diabetic complications. The more inten-
sive the treatment, the better the chance to delay
the onset and the progression of complications [2].
Side eﬀects of more intensive therapy are body
weight gain and an increased frequency of hypo-
glycaemic episodes. In particular, the frequency of
hypoglycaemia can inﬂuence a patient’s life [3]. It
can be diﬃcult to ﬁnd a balance between food
intake, exercise and insulin dose to reach a satis-
factory metabolic control. This may aﬀect health
related quality of life (QOL) in many diﬀerent
ways [4].
In recent years, QOL consisting of physical,
psychological and social aspects has become more
important in health care. Diﬀerent instruments
have been developed to measure QOL in various
patient categories: generic instruments to allow
comparisons with other patient populations or
samples of the general population and disease-spe-
ciﬁc instruments to assess the inﬂuence of diﬀerent
aspects of a speciﬁc disease and its treatment [5–9].
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The attention paid to the QOL of patients with
DMT1 is very important [4, 10–13]. The patients
with DMT1 have a lifelong, chronic and serious
disease and will develop several micro- and mac-
rovascular complications, which will have a daily
impact on their physical and psychological func-
tioning. In addition to the fact that DMT1 is a
serious chronic disease, it is a frequently occurring
disease.
It is not clear, which factors inﬂuence QOL the
most, how the individuals appraise the diﬀerent
aspects of the regimen, or which patients have the
lowest QOL, or whether clinicians can inﬂuence
those factors negatively inﬂuencing QOL. For
these reasons it is of great importance to have
good insight in the factors inﬂuencing the well
being of this group of patients.
In this study we addressed the following ques-
tions: How do subjects with DMT1 assess their
QOL compared to persons of comparable age
from the general population? Which factors in-
ﬂuence the QOL of patients with DMT1?
Methods
Patients
From January 1995 to January 1996, 293 consec-
utive DMT1 patients, treated at the outpatient
clinic of the Isala Clinics in Zwolle, the Nether-
lands, were invited to participate in the study. A
group of 281 patients agreed to participate and
was investigated in 1995. DMT1 was deﬁned as
starting insulin therapy within 6 months after the
ﬁrst signs of diabetes mellitus and before the age of
30 years, or the absence of C-peptide secretion.
Approval was obtained from the Hospital Scien-
tiﬁc and Ethical Committee. All patients gave in-
formed consent.
Quality of life
QOL was assessed using two generic instruments,
the RAND-36-item Health Survey (RAND-36)
and the EuroQol. Questionnaires were sent by
mail to the patient’s home address. Patients were
asked to ﬁll in the questionnaires at home. Upon
the visit to the outpatient clinic, the patients re-
turned the completed questionnaires to the diabe-
tes specialist nurse. Patients who did not return the
completed questionnaires when visiting the clinic
were asked to send their completed questionnaires
afterwards.
The RAND-36 is a self-administered question-
naire containing 36 items involving eight diﬀerent
domains: physical functioning, role limitations due
to physical problems, bodily pain, general health
perception, vitality, social functioning, role limi-
tations due to emotional problems, and mental
health. For each domain, scores were coded,
summed up and transformed to a scale from 0
(worst health) to 100 (best health) [14, 15]. In ad-
dition, physical and mental component summary
scores were determined (PCS/MCS) [16]. The
questionnaire takes about 10 min to complete. The
instrument has been translated in Dutch [17] and
validated for the Dutch population [18].
The EuroQol is a simple generic measure, de-
veloped by a multidisciplinary group of research-
ers from ﬁve European countries, consisting of two
parts (EQ-5D and EQ-VAS). For the EQ-5D part,
there are ﬁve questions covering the areas mobili-
ty, self-care, usual activities, pain/discomfort and
anxiety/depression. Each dimension is divided into
three levels: no problem, some/moderate problems
and extreme problems/unable to perform. A re-
spondent’s health state is deﬁned by combining
one level from each of the ﬁve dimensions (EQ-
5D). A total of 243 possible health states can be
deﬁned in this way. Valuations of these health
states have been made by the UK general public,
using a valuation technique called time trade-oﬀ.
The values, or utilities, are scaled on a scale on
which 0 is the value of dead and 1 is the value of
perfect health [19]. Furthermore a single overall
score can be elicited using the EuroQol ther-
mometer, a self-rated health status using a gra-
duated (0–100) visual analogue scale, similar to a
thermometer (EQ-VAS). The EuroQol takes about
2 min to complete and has been validated for the
Dutch situation [20].
Clinical data
One trained physician (J.H.A.) examined all
patients according to a standardised protocol.
Demographic data (age, sex, married/having a
partner, level of education) and data concerning
therapy (HbA1c, frequency of insulin injection,
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frequency of self-monitoring of blood glucose and
presence of hyperglycaemic complaints) were re-
corded. Patients recorded all hypoglycaemic events
(‘did you have a hypo in the past 3 months?’)
during the 3 months preceding the outpatient visit.
Patients were asked to report whether they had one
of six diﬀerent hyperglycaemic complaints during
the last three months (yes/no): tiredness, weight
loss, pruritus, thirst, polyuria and polydipsia
(Cronbach’s a 6-items 0.74). Metabolic control was
assessed by measuring glycosylated haemoglobin
A1c (HbA1c). The presence of comorbidity (one or
more diseases besides diabetes) was assessed using
a list of 26 chronic diseases [21].
Macrovascular complications
Patients were classiﬁed as having macrovascular
complications when one or more of the following
diagnoses was present: angina pectoris, myocardial
infarction, intermittent claudication, transient is-
chaemic attack (TIA), or a cerebrovascular acci-
dent (CVA). The physician recorded these
diagnoses in the clinical status of all patients.
Microvascular complications
Patients with retinopathy, neuropathy or nephro-
pathy were diagnosed as having microvascular
complications.
Retinopathy
The ophthalmologist examined all patients annu-
ally. The degree of diabetic retinopathy was as-
sessed by fundoscopy in mydriasis. The classiﬁ-
cation of diabetic retinopathy used was based on
Jong [22]: no retinopathy (¼ 0), background ret-
inopathy (¼ I), preproliferative (¼ II), and pro-
liferative diabetic retinopathy (¼ III).
Retinopathy was scored positive, when any type
of retinopathy was present in either eye. When the
degree of retinopathy was diﬀerent in two eyes, the
highest degree was scored.
Neuropathy
Sensitivity was tested by the Semmes–Weinstein
pressure aesthesiometer [23]. At ﬁve dorsal and
plantar sites on the feet sensitivity was tested using
six diﬀerent monoﬁlaments. When the monoﬁla-
ment 5.07 was not felt at one of the 10 test sites,
patients were diagnosed as having neuropathy.
Nephropathy
The 24-hours urinary excretion of albumin
(UAER) was measured yearly. UAER was con-
sidered abnormal when it was P30 mg/24 hours.
Micro-albuminuria was deﬁned as 30–300 mg/
24 hours and macro-albuminuria as P300 mg/
24 hours. All patients with micro-albuminuria or
macro-albuminuria were deﬁned as having
nephropathy [24–26].
At the time of the study (1995) patients with a
micro-albuminuria >100 mg/24 hours received an
angiotensin converting enzyme inhibitor (ACE-
inhibitor) in the Isala Clinics. We classiﬁed ACE-
inhibitor users as having nephropathy, unless
ACE-inhibition was started speciﬁcally for hyper-
tension.
Analysis
QOL of patients was compared with the QOL of
the general population using the T-test for inde-
pendent samples. Univariate and multivariate
stepwise regression analyses (with the PCS, MCS,
the EuroQol 5-D, and the EuroQol-VAS being the
dependent variables) were performed to investigate
the relationships between QOL scores (RAND-36
and EuroQol) and demographic data (sex, age,
marital status, level of education) and data con-
cerning the disease and its therapy (e.g. frequency
of insulin injection, HbA1c, acute and chronic
complications). Furthermore we calculated the
Spearman rank order correlations between the
domains of the RAND-36 and the dimensions of
the EuroQol. We expected correlations between
‘mobility’ and the domains ‘physical functioning’
and ‘role physical’, between ‘self-care’ and ‘physi-
cal functioning’ and ‘role physical’, between ‘usual
activities’ and most domains of the RAND-36,
between ‘pain/discomfort’ and ‘bodily pain’ and
between ‘anxiety/depression’ and the more mental
domains of the RAND-36. We considered corre-
lations <0.39 as weak, 0.40–0.59 as moderate and
>0.60 as strong.
Relationships were considered statistically sig-
niﬁcant when p-values O 0.05 were reached. Data




A total of 281 adult patients with DMT1 entered
the study. Baseline characteristics of the study
population are shown in Table 1. Mean age in the
study population was 38.2 years and 54.4% were
men. Most patients received intensive therapy
(87.9%) and self-monitored their blood glucose
values. Almost half of the patients had microvas-
cular complications (47.1%) (Table 1). Most pa-
tients with retinopathy had grade I diabetic
retinopathy, almost always in both eyes. Of the
patients with nephropathy (n ¼ 53), 21% had
macro-albuminuria (n ¼ 11), the others micro-al-
buminuria. About 10% of the patients had mac-
rovascular complications, the most frequently
reported diagnoses being angina pectoris and in-
termittent claudication. Most patients with com-
orbidity had one or two other chronic medical
conditions besides their diabetes.
The QOL questionnaires were completed by 274
patients (97.5%) (Table 2). The RAND-36 QOL
domain scores were comparable with those of
persons of comparable age in the Dutch general
population [15], except for the General Health
domain that was lower than in the general popu-
lation (p ¼ 0.022) and the Bodily Pain domain that
was higher than in the general population (p =
0.010). The EQ-5D and the EQ-VAS-score were
lower in our study group compared to persons of
comparable age from the UK general population
[27].
Univariate analysis showed that females repor-
ted a lower QOL (MCS and EQ-5D) than males.
Older patients had lower scores for the PCS, the
EQ-5D and the EQ-VAS. Patients having a part-
ner and patients using alcohol reported a higher
MCS and EQ-VAS. A higher HbA1c was associ-
ated with a lower EQ-VAS. Patients with contin-
uous insulin therapy had a lower MCS and a lower
EQ-5D, whereas patients with four-times daily
insulin injection reported a higher PCS, than pa-
tients with 2–3 injections daily. Patients with a
high frequency of self-monitoring had lower scores
for the PCS, the EQ-5D and the EQ-VAS. Patients
having hyperglycaemic complaints, macrovascular
complications and comorbidity reported a lower
QOL (PCS, MCS, EQ-5D, EQ-VAS). Patients
having microvascular complications also reported
a lower QOL (MCS, EQ-5D and EQ-VAS).
Multivariate analysis for the RAND-36 and
the EuroQol showed that the presence of a
macrovascular complication had the most pro-
nounced negative inﬂuence on QOL (Table 3).
Older age, higher frequency of self-monitoring a
week, macrovascular complications and comor-
bidity were associated with lower PCS scores
(Table 3). The assessment of the impact of age and
frequency of self-monitoring is based on a com-
bination of the beta coeﬃcient with the observed
range in values. For example, a decrease in PCS
score of 0.91/10 years increase in age was seen. In
contrast, younger age, unmarried status, hyper-
Table 1. Personal and disease-speciﬁc characteristics of the
study population
Number of patients 281
Gender (men) 153 (54.4%)
Age (years) 38.2 (12.4)
Duration of diabetes (years) 17.2 (10.7)
Married/cohabiting 242 (88.3%)
High level of education 90 (32%)
Smoking 91 (32.4%)
Alcohol use 172 (61.2%)
Systolic blood pressure (mm Hg) 139.1 (18.4)
Diastolic blood pressure (mm Hg) 82.9 (8.3)
Ratio of total cholesterol (mmol/l)/
HDL-cholesterol (mmol/l)
3.8 (1.2)
Body mass index (kg/m2) 24.7 (3.2)
Hba1c (%) 8.3 (1.9)





Self-monitoring of blood glucose 275 (100%)
Number of control measurements
per week
11.9 (11.6)














(one or more chronic medical
condition)
161 (58.5%)
Values are number of patients or means with valid percentage
or standard deviation between parentheses.
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glycaemic complaints and macrovascular compli-
cations were associated with lower MCS scores
(Table 3). The presence of hyperglycaemic com-
plaints, macrovascular complications and comor-
bidity were associated with lower EQ-5D scores
(Table 3). High level of education, higher Hba1c,
higher frequency of self-monitoring, hyperglycae-
mic complaints and macrovascular complications
were associated with lower EQ-VAS scores
(Table 3).
The Spearman rank correlations between the
domains of the RAND-36 and the EuroQol
Table 2. Comparison of QoL scores seen in the study population with scores seen in the general population
This study General population [15]
DMT1 N = 274 N = 195
Age (years) 38.2 35–44
Percentage men 54.4% 31%
RAND-36 p-Values
Physical functioning 90.4 (14.7) 90.0 (14.4) 0.769
Role physical 82.8 (32.4) 82.9 (32.0) 0.974
Bodily paina 88.7 (17.8) 83.8 (21.7) 0.010
General health 68.0 (20.1) 74.0 (20.7) 0.002
Vitality 67.5 (20.0) 67.1 (18.9) 0.826
Social functioning 86.9 (20.0) 88.0 (17.6) 0.529
Role emotional 84.0 (31.8) 82.2 (33.5) 0.558
Mental health 76.6 (17.3) 76.9 (18.0) 0.857
DM type n = 274 General population [27] n = 561
EuroQol
Age (years) 38.3 35–44
Percentage men 54.4% 45.6%
EQ-5D 0.88 (0.17) 0.91 (0.16) 0.052
EQ-VAS 80.8 (15.2) 86.6 (13.8) <0.001
Values are means with standard deviations between parentheses. p-Values concerns T-test for independent samples.
aHigher bodily pain score indicates less pain.











Age (per year) 0.091 (p = 0.015) 0.118 (p = 0.021)
Married/cohabiting 5.669 (p = 0.002)
High level of education 5.432 (p = 0.006)
Hba1c (%) 1.241 (p = 0.012)
Frequency of insulin injection:
Four-times a day relative
to 2–3 times
Continuous relative to 2–3 times
Self-monitoring a week 0.167 (p<0.001) 0.224 (p = 0.005)
Hypoglycaemic complaints
Hyperglycaemic complaints 7.428 (p<0.001) 0.071 (p = 0.002) 8.716 (p<0.001)
Microvascular complications
Macrovascular complications 8.468 (p<0.001) 6.698 (p = 0.002) 0.146 (p<0.001) 10.016 (p = 0.002)
Comorbidity 2.323 (p = 0.0010) 0.078 (p = 0.001)
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dimensions are shown in Table 4. The correlations
between mobility and ‘physical functioning’ and
‘role physical’ were moderate. The dimension self-
care did not show any signiﬁcant correlation with
one of the RAND-36 domains, while the usual ac-
tivities dimension was moderately/strongly corre-
lated with all domains of the RAND-36. Pain/
discomfort was strongly correlated with the domain
‘bodily pain’. Anxiety/depression was particularly
correlated with the domain ‘mental health’.
Discussion
QOL measured in our study population was
comparable with the QOL of persons of compa-
rable age in the Dutch general population, when
using the RAND-36, except for the domains of
‘bodily pain’ and ‘general health’, which were re-
spectively higher and lower than in the general
population. We cannot explain why patients with
DMT1 reported less pain (i.e. higher RAND-36
bodily pain scores) than patients in the general
population. A possible explanation is the fact that
the percentage of females in the general population
sample was higher than in our cohort (69 vs. 46%)
and that females tend to report more symptoms
such as bodily pain [15, 28]. The EuroQol gave
lower QOL levels for subjects with DMT1 than
patients in a UK sample of the general population.
Wikblad et al. [29] reported a QOL equal to per-
sons in the general population just as in our study
(mean age 43.5 years). In the study of Wandell
et al. [30], diabetic patients reported a QOL lower
than persons in a population sample. However
their cohort was older (mean 51.5 year) than our
cohort (mean 38.2 years). Recently Hahl et al. [31]
reported a lower health related QOL for patients
with DMT1 (in the age groups 35–44 and 45–54)
compared to the general population, measured
with the 15-D, a generic measure.
The frequency of macrovascular complications
was relatively low (9.6%) in our cohort, whereas
microvascular complications were more prevalent
(47.1%), as could be expected with this duration of
diabetes (mean 17.2 years). Almost by deﬁnition,
the early stages of microvascular complications
will not have an impact on daily life. Most com-
plications were in the early stages in our patient
group.
When considering our results of the uni- and
multivariate regression analyses it is important to
remember that statistically signiﬁcant associations
are not the same as clinically important relation-
ships. The problem is the interpretation of one’s
statistical exercises [32]. Although the developers
of the instruments do not promote the use of the
smallest change which is still considered clinically
signiﬁcant, score changes of >1 point for the
summary scores [33], 0.05 points for the EQ-5D
and ﬁve points for the EQ-VAS (EuroQol group)
can be used as a guide. If we apply these arbitrary
cut-oﬀ points, the components found in the re-
gression models have a clinically important nega-
tive impact on the health related QOL of patients
with DMT1. We can conclude that the presence of
macrovascular complications deﬁnitely has a large
negative impact on the health related QOL of
patients with DMT1. Other studies also reported a
worse QOL, measured with generic as well as di-
abetes-speciﬁc instruments, when late complica-
tions were present, but these studies did not
diﬀerentiate between microvascular and macro-
vascular complications [29, 34–36].
Table 4. Spearman rank order correlations between domains of the RAND-36 and the EuroQol
EuroQoL
RAND-36 Mobility Self-care Usual activities Pain/discomfort Anxiety/depression
Physical functioning 0.490 (p<0.001) 0.025 (p=0.686) 0.509 (p<0.001) 0.475 (p<0.001) 0.218 (p<0.001)
Role physical 0.401 (p<0.001) 0.062 (p=0.309) 0.700 (p<0.001) 0.390 (p<0.001) 0.389 (p<0.001)
Bodily pain 0.343 (p<0.001) 0.039 (p=0.523) 0.478 (p<0.001) 0.717 (p<0.001) 0.279 (p<0.001)
General health 0.324 (p<0.001) 0.079 (p=0.195) 0.480 (p<0.001) 0.431 (p<0.001) 0.323 (p<0.001)
Vitality 0.227 (p<0.001) 0.001 (p=0.993) 0.573 (p<0.001) 0.337 (p<0.001) 0.408 (p<0.001)
Social functioning 0.272 (p<0.001) 0.048 (p=0.434) 0.558 (p<0.001) 0.388 (p<0.001) 0.484 (p<0.001)
Role emotional 0.166 (p=0.006) 0.066 (p=0.280) 0.700 (p<0.001) 0.314 (p<0.001) 0.389 (p<0.001)
Mental health 0.196 (p=0.001) 0.020 (p=0.737) 0.402 (p<0.001) 0.332 (p<0.001) 0.531 (p<0.001)
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Hahl et al. [31], also reported a signiﬁcant neg-
ative inﬂuence on QOL by the symptoms of long-
term micro- and macrovascular complications. In
this study however, they used self-reported symp-
toms of the complications instead of the objective
scoring of complications in our cohort. The pres-
ence of microvascular complications seemed to be
of minor inﬂuence on the QOL in our study. In the
multivariate regression analyses these complica-
tions did not have a statistically signiﬁcant inﬂu-
ence on QOL. Perhaps this ﬁnding can be
explained by the fact that a light to moderate de-
gree of neuropathy, retinopathy and/or nephro-
pathy will not even cause minor symptoms or
complaints and thus will not interrupt daily life in
subjects with DMT1. In contrast, macrovascular
complications will virtually always cause manifest
symptoms or complaints. However, two studies
described an inﬂuence of microvascular compli-
cations on QOL [37, 38]. Hanestad et al. reported
that the presence of nephropathy had a negative
eﬀect on QOL, whereas neuropathy was associated
with a better QOL in her study. The severity of
complications was not properly clariﬁed. Wu et al.
observed a higher QOL (measured with the SF-36)
for patients with retinopathy and concluded that
further study was needed to explore the underlying
reasons for this surprising ﬁnding. The UK
Prospective Diabetes Study (UKPDS) reported
for patients with diabetes mellitus type 2 (DMT2)
the same negative impact on QOL by the pre-
sence of long-term complications [39] . Patients
with macrovascular complications reported a
lower EQ-5D, while patients with microvascular
complications reported more tension and a
total mood disturbance (Proﬁle of Mood State).
In this study, too, the generic measure (EQ-5D)
did not measure a lowered QOL by microvascular
complications. Perhaps the generic instru-
ments, such as the EQ-5D, are not sensitive en-
ough to measure the sometimes mild symptoms
associated with the microvascular complications.
Redekop et al. [40] however did ﬁnd an associa-
tion between microvascular complications and re-
duced QOL.
Another negative inﬂuence on QOL is the
presence of hyperglycaemic complaints. These had
a negative association with the RAND-36 and the
EuroQol scores, whereas remarkably the presence
of hypoglycaemic events was of less importance.
Only the univariate analysis for the EQ-VAS
showed a signiﬁcant negative inﬂuence of the
presence of hypoglycaemic events. However, in the
intensive treatment group of the Diabetes Control
and Complications Trial the presence of hypo-
glycaemia was the only factor which tended to
cause a decreased QOL, by more symptomatic
distress [3].
In our study, patients receiving continuous in-
sulin therapy reported a lower MCS and EQ-5D.
Such an intensive therapy obliges the patients to
monitor their blood glucose levels regularly.
However, it was the frequency of self-monitoring,
which remained of signiﬁcant negative inﬂuence in
the multivariate analysis of both the PCS and the
EQ-VAS. The correlation between the frequency
of self-monitoring and continuous insulin therapy
was moderate (0.503, p ¼ 0.010). Therefore, the
obligatory high frequency of self-monitoring as-
sociated with continuous insulin therapy could
explain the perceived lower QOL of patients using
continuous therapy.
The ﬁnding that women, older patients and
patients without a partner reported a lower QOL
conﬁrms the results of other studies [29, 34, 35, 37,
41]. The positive inﬂuence of age on the MCS has
not been described before. Perhaps the fact that
these patients have learned to cope with a chronic
disease like DMT1, positively inﬂuences mental
state. The ﬁnding that patients with a higher ed-
ucation reported a lower EQ-VAS score is new.
The reason for this ﬁnding is unclear.
What is the relevance of knowing these rela-
tionships between patient characteristics and
QOL? Many personal characteristics such as sex
and age cannot be inﬂuenced.
Nevertheless it is of great importance for clini-
cians to be aware of patients likely to have a lower
QOL. For other factors, such as the frequency of
self-monitoring, it might be possible to try to re-
duce the frequency to what is absolutely necessary.
Most correlations between the dimensions of the
EQ and the domains of the RAND-36 were as
expected. Oddly enough the dimension ‘self-care’
did not show any statistically signiﬁcant correla-
tion with any RAND-36 domain. It is possible that
this item, concerning washing and dressing oneself,
is too speciﬁc to be reﬂected in the total score for a
RAND domain. Usual activities are shown to be
inﬂuenced by both physical and mental factors.
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The highest correlation of the dimension anxiety/
depression was with the mental health domain, the
RAND domain with the highest correlation with
the MCS [33].
The response rates for both instruments were
equal, so the length of the RAND-36 did not seem
to be a problem for this group of patients, but this is
likely due to their incorporation into one ques-
tionnaire. Most relationships between patient
characteristics and QOL were assessed by both in-
struments, except for age and having a partner by
the RAND-36 and the level of education and
Hba1c by the EuroQol. The shortness and sim-
plicity of the EuroQol as well as its capacity to
make economic evaluations possible are major
advantages of this instrument. Still, the more de-
tailed information (eight diﬀerent domains) and the
distinction between a ‘physical score’ and a ‘mental
score’ are clear advantages of the RAND-36.
Longitudinal data and comparison with results
of several diabetes-speciﬁc QOL questionnaires
should help to establish which instrument might be
most appropriate to measure QOL in patients with
DMT1.
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